Bristol-Myers Squibb (BMY) P/E (2010 - 2026)
Bristol-Myers Squibb (BMY) P/E from Mar 31, 2010 to Jul 20, 2026. The TTM Bristol-Myers Squibb (BMY) P/E is 14.17. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Bristol-Myers Squibb (BMY)
| Year | P/E | Change |
|---|---|---|
| 2026 | 14.17 | -7.25% |
| 2025 | 15.28 | -195.19% |
| 2024 | -16.05 | -217.54% |
| 2023 | 13.65 | -48.55% |
| 2022 | 26.54 | +23.58% |
| 2021 | 21.47 | -55.77% |
| 2020 | 48.55 | +196.16% |
| 2019 | 16.39 | -11.10% |
| 2018 | 18.44 | -17.57% |
| 2017 | 22.37 | -2.12% |
| 2016 | 22.86 | -50.38% |
| 2015 | 46.07 | +26.69% |
| 2014 | 36.36 | -52.69% |
| 2013 | 76.87 | +178.26% |
| 2012 | 27.62 | +75.02% |
| 2011 | 15.78 | -8.97% |
| 2010 | 17.34 | N/A |
Comparison Bristol-Myers Squibb (BMY) P/E with competitors
Bristol-Myers Squibb (BMY) P/E is 14.17.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -28.65% |
| PFE | Pfizer Inc | 11.65 | -17.74% |
| NVO | Novo Nordisk | 11.79 | -16.77% |
| GSK | GSK Plc | 12.10 | -14.57% |
| SNY | Sanofi | 12.12 | -14.42% |
| OGN | Organon & Company | 14.33 | +1.12% |
| BIIB | Biogen Inc | 17.41 | +22.85% |
| GILD | Gilead Sciences Inc | 17.75 | +25.25% |
| NVS | Novartis AG | 21.60 | +52.44% |
| JNJ | Johnson & Johnson | 22.09 | +55.90% |
| AMGN | AMGEN Inc | 24.75 | +74.70% |
| MRK | Merck & Co Inc | 26.93 | +90.06% |
| AZN | Astrazeneca plc | 28.44 | +100.76% |
| LLY | Lilly(Eli) & Company | 48.44 | +241.92% |
| ABBV | Abbvie Inc | 139.08 | +881.66% |